<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Gossamer Bio Inc — News on 6ix</title>
<link>https://6ix.com/company/gossamer-bio-inc</link>
<description>Latest news and press releases for Gossamer Bio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/gossamer-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835794278dffbe2df0f8679.webp</url>
<title>Gossamer Bio Inc</title>
<link>https://6ix.com/company/gossamer-bio-inc</link>
</image>
<item>
<title>Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>- Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic</description>
</item>
<item>
<title>Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-topline-results-from-the-phase-3-prosera-study-evaluating-seralutinib-in-pulmonary-arterial-hypertension</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-topline-results-from-the-phase-3-prosera-study-evaluating-seralutinib-in-pulmonary-arterial-hypertension</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the</description>
</item>
<item>
<title>Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-inducement-grant-223000855</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-inducement-grant-223000855</guid>
<pubDate>Thu, 08 Jan 2026 22:30:00 GMT</pubDate>
<description>SAN DIEGO, January 08, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5th, 2026, to three non-executive employees of non-qualified stock</description>
</item>
<item>
<title>Gossamer Bio to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-participate-upcoming-investor-conferences-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-participate-upcoming-investor-conferences-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and</description>
</item>
<item>
<title>Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-third-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-third-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>- Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash</description>
</item>
<item>
<title>Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-enters-option-agreement-acquire-respira-therapeutics-and-its-lead</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-enters-option-agreement-acquire-respira-therapeutics-and-its-lead</guid>
<pubDate>Thu, 25 Sep 2025 04:00:00 GMT</pubDate>
<description>- RT234 is an investigational inhaled, as needed (PRN) vardenafil formulation for PAH and PH-ILD, where no on demand treatments exist - - Capital-efficient</description>
</item>
<item>
<title>Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/respira-therapeutics-enters-into-agreement-with-gossamer-bio-gossamer-granting-gossamer-option-to-acquire-respira-from-samsara-biocapital</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/respira-therapeutics-enters-into-agreement-with-gossamer-bio-gossamer-granting-gossamer-option-to-acquire-respira-from-samsara-biocapital</guid>
<pubDate>Thu, 25 Sep 2025 04:00:00 GMT</pubDate>
<description>- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH</description>
</item>
<item>
<title>Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-presentations-european-respiratory-society-ers-congress-2025</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-presentations-european-respiratory-society-ers-congress-2025</guid>
<pubDate>Mon, 22 Sep 2025 04:00:00 GMT</pubDate>
<description>- One Oral and Four Poster Presentations Highlight Seralutinib’s Potential Across Pulmonary Hypertension and Fibrotic Lung Disease - SAN DIEGO--(BUSINESS</description>
</item>
<item>
<title>Gossamer Bio to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-present-upcoming-investor-conferences-2025-08-29</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-present-upcoming-investor-conferences-2025-08-29</guid>
<pubDate>Fri, 29 Aug 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and</description>
</item>
<item>
<title>Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-second-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-second-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Tue, 05 Aug 2025 04:00:00 GMT</pubDate>
<description>- Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD</description>
</item>
<item>
<title>Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-completion-enrollment-registrational-phase-3-prosera-study</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-completion-enrollment-registrational-phase-3-prosera-study</guid>
<pubDate>Mon, 16 Jun 2025 04:00:00 GMT</pubDate>
<description>- Enrollment Completed in Ongoing Registrational PROSERA Phase 3 Study in PAH - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026</description>
</item>
<item>
<title>Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-first-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-first-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Thu, 15 May 2025 04:00:00 GMT</pubDate>
<description>- Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results</description>
</item>
<item>
<title>Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announce-first-quarter-2025-financial-results-and-host-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announce-first-quarter-2025-financial-results-and-host-conference-call</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and</description>
</item>
<item>
<title>Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-present-preclinical-data-american-thoracic-society-ats-2025</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-present-preclinical-data-american-thoracic-society-ats-2025</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization</description>
</item>
<item>
<title>Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-fourth-quarter-and-full-year-2024-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-fourth-quarter-and-full-year-2024-financial-results-and</guid>
<pubDate>Thu, 13 Mar 2025 04:00:00 GMT</pubDate>
<description>- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half</description>
</item>
<item>
<title>Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-present-clinical-and-preclinical-data-pulmonary-vascular-research</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-present-clinical-and-preclinical-data-pulmonary-vascular-research</guid>
<pubDate>Tue, 28 Jan 2025 05:00:00 GMT</pubDate>
<description>- Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH - SAN DIEGO--(BUSINESS</description>
</item>
<item>
<title>Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-third-quarter-2024-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-third-quarter-2024-financial-results-and-provides-business</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>- $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS),</description>
</item>
<item>
<title>Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-data-presentations-european-respiratory-society-congress-2024</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-data-presentations-european-respiratory-society-congress-2024</guid>
<pubDate>Mon, 26 Aug 2024 04:00:00 GMT</pubDate>
<description>- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna - SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a</description>
</item>
<item>
<title>Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-second-quarter-2024-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-announces-second-quarter-2024-financial-results-and-provides-business</guid>
<pubDate>Mon, 12 Aug 2024 04:00:00 GMT</pubDate>
<description>- $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a</description>
</item>
<item>
<title>Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference</title>
<link>https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-to-provide-updated-seralutinib-torrey-open-label-extension-data-at-the</link>
<guid isPermaLink="true">https://6ix.com/company/gossamer-bio-inc/news/gossamer-bio-to-provide-updated-seralutinib-torrey-open-label-extension-data-at-the</guid>
<pubDate>Tue, 14 May 2024 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization</description>
</item>
</channel>
</rss>